BHC

Business Context and Reporting Period

Company: Biovail Corporation (now Bausch Health Companies Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: Biovail is a fully-integrated pharmaceutical company focused on cardiovascular disease, central nervous system (CNS) disorders, and pain management. The company utilizes proprietary drug delivery technologies to develop controlled-release and rapid-dissolve formulations. In 2003, the company transitioned from a primarily Canadian commercial operation to expanding its U.S. sales and marketing infrastructure, relocating its U.S. headquarters to Bridgewater, New Jersey.

Key Financial Metrics (U.S. GAAP)

Note: Under Canadian GAAP, Net Loss attributable to common shareholders was $(40.3) million for 2003.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 5% to $823.7 million. This was driven by a 129% increase in "Core Products" (actively promoted products) to $322.5 million, primarily due to the launch of Cardizem LA, Teveten HCT, Zovirax Cream, and Wellbutrin XL. This growth was partially offset by a 35% decline in Legacy products and a 44% decline in Generic products.
• Profitability Decline: Despite revenue growth, the company reported a net loss of $27.3 million compared to a net income of $87.8 million in 2002. This was primarily due to significant one-time charges totaling $239.7 million, including $124.7 million for acquired research and development, $61.3 million to extinguish a royalty obligation to Reliant Pharmaceuticals, and $45.1 million for asset write-downs.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 46% to $242.8 million due to the expansion of U.S. commercial operations and relocation costs. Research and development expenses increased 66% to $86.6 million to support new product launches and clinical trials.
• Liquidity Improvement: Working capital improved significantly from a negative $23.5 million in 2002 to a positive $149.9 million in 2003, driven by higher cash balances and inventory build-up for new product launches.

Guidance, Outlook, and Risks

Outlook and Strategy: Management expects continued investment in 2004 to strengthen sales and marketing infrastructure and expand manufacturing capacity, which may limit earnings growth in the near term. The company plans to out-license select pipeline products (e.g., Ralivia ER, Glumetza) while focusing its own sales force on promoted products like Cardizem LA and Teveten. Revenue from Wellbutrin XL is expected to increase in 2004 due to a full-year contribution and tiered supply pricing.

Key Risks and Contingencies:

• Regulatory Inquiries: The company is subject to informal inquiries by the SEC regarding its 2003 financial performance and accounting matters, and by the Ontario Securities Commission (OSC) regarding trading of securities prior to press releases in October 2003. An inquiry by the U.S. Office of the Inspector General (OIG) is also underway regarding marketing programs for Cardizem LA.
• Legal Proceedings: The company faces various litigation, including patent infringement suits (e.g., Torpharm, RhoxalPharma), antitrust class actions regarding Tiazac, and product liability claims related to Dura-Vent. Arbitration proceedings were initiated against Teva Pharmaceuticals regarding generic product net sales calculations.
• Accounting Restatement: The company identified a weakness in internal controls regarding the application of exchange rates to a Canadian dollar-denominated long-term obligation, resulting in a restatement of interim 2003 results.
• Market Risks: Risks include patent expiration, generic competition, reliance on third-party manufacturers, and the ability to obtain regulatory approvals for pipeline products.

Investor Verification Checklist

• Regulatory Investigations: Verify the status and potential financial impact of the ongoing SEC, OSC, and OIG inquiries.
• One-Time Charges: Assess the sustainability of earnings by analyzing the $239.7 million in specific event charges (acquired R&D, asset write-downs, royalty extinguishment) that drove the 2003 net loss.
• Product Pipeline: Monitor the regulatory approval status of key pipeline products (Ralivia ER, Glumetza, Ralivia FlashDose) which are critical to future revenue growth.
• Generic Competition: Evaluate the impact of generic entry on legacy products like Tiazac and Cardizem CD, which contributed to revenue declines in those categories.
• Internal Controls: Review the remediation steps taken regarding the identified internal control weakness related to foreign exchange accounting.